PubMed Health⌕ Search

PubMed · 16821831

Energy transfer between polyatomic molecules. 3. Energy transfer quantities and probability density functions in self-collisions of benzene, toluene, p-xylene and azulene.

Abstract

This paper is the third and last in a series of papers that deal with collisional energy transfer, CET, between aromatic polyatomic molecules. Paper 1 of this series (J. Phys. Chem. B 2005, 109, 8310) reports on the mechanism and quantities of CET between an excited benzene and cold benzene and Ar bath. Paper 2 in the series (J. Phys. Chem., in press) discusses CET between excited toluene, p-xylene and azulene with cold benzene and Ar and CET between excited benzene colliding with cold toluene, p-xylene and azulene. The present work reports on CET in self-collisions of benzene, toluene, p-xylene and azulene. Two modes of excitation are considered, identical excitation energies and identical vibrational temperatures for all four molecules. It compares the present results with those of papers 1 and 2 and reports new findings on average vibrational, rotational, and translational energy, , transferred in a single collision. CET takes place mainly via vibration to vibration energy transfer. The effect of internal rotors on CET is discussed and CET quantities are reported as a function of temperature and excitation energy. It is found that the temperature dependence of CET quantities is unexpected, resembling a parabolic function. The density of vibrational states is reported and its effect on CET is discussed. Energy transfer probability density functions, P(E,E'), for various collision pairs are reported and it is shown that the shape of the curves is convex at low temperatures and can be concave at high temperatures. There is a large supercollision tail at the down wing of P(E,E'). The mechanisms of CET are short, impulsive collisions and long-lived chattering collisions where energy is transferred in a sequence of short internal encounters during the lifetime of the collision complex. The collision complex lifetimes as a function of temperature are reported. It is shown that dynamical effects control CET. A comparison is made with experimental results and it is shown that good agreement is obtained.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V Bernshtein, I Oref. 2006-07-13. Energy transfer between polyatomic molecules. 3. Energy transfer quantities and probability density functions in self-collisions of benzene, toluene, p-xylene and azulene.. https://doi.org/10.1021/jp055612q

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗